Medindia

X

BioNumerik Initiates Treatment of Patients in Global Phase III Clinical Trial of Tavocept(TM) to Confirm Substantial Survival Increases Previously Observed in Most Common Type of Lung Cancer

Thursday, January 21, 2010 General News J E 4
Advertisement
European Journal of Clinical & Medical Oncology Publishes Meta-Analysis of Phase II and Phase III Trials Supporting Tavocept's Potential to Increase Lung Cancer Survival

Contact:

BioNumerik Pharmaceuticals, Inc.

Public Relations Department

(210) 614-1701, ext. 500

email:  publicrelations@bnpi.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Neuralstem Announces First Patient Treated in ALS ...
S
BioCryst Pharmaceuticals to Announce Fourth Quarte...